QIAGEN Shares Drop Amid EMA Review, Yet Liquid‑Biopsy & NAAT Growth Persists
QIAGEN’s Q1 performance shows a mixed German market result, with solid liquid‑biopsy and NAAT science driving future growth despite current regulatory delays.
5 minutes to read